Kevin J. Harrington
凯文·哈灵顿
MBBS, PhD, FRCP, FMedSci
Professor of Biological Cancer Therapy; Honorary Consultant Clinical Oncologist生物癌症治疗学教授；荣誉顾问临床肿瘤学家
👥Biography 个人简介
Kevin J. Harrington, MBBS, PhD is Professor of Biological Cancer Therapy at The Institute of Cancer Research and Honorary Consultant Clinical Oncologist at The Royal Marsden Hospital, London. He is an internationally recognized leader in translational oncology for head and neck cancers, with particular expertise in EGFR-targeting agents, cetuximab-based combinations, and novel oncolytic virus strategies. His laboratory and clinical programs have made fundamental contributions to understanding resistance mechanisms to cetuximab in HNSCC and to validating oncolytic herpes simplex virus (T-VEC) in combination with checkpoint immunotherapy. Dr. Harrington was a key investigator in the LBA43 study exploring the addition of durvalumab to cetuximab plus radiotherapy in locally advanced HNSCC, and contributed pivotal biomarker work characterizing EGFR pathway alterations. He has authored over 300 peer-reviewed publications and serves on the editorial boards of major oncology journals. He is an elected Fellow of the Academy of Medical Sciences (FMedSci).
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Cetuximab Mechanisms and Resistance in HNSCC
Defined molecular mechanisms of de novo and acquired resistance to cetuximab, including KRAS, PI3K, and MET pathway alterations, providing rationale for combination strategies to overcome EGFR inhibitor resistance in head and neck cancer.
Oncolytic Virus Therapy for HNSCC
Conducted foundational clinical trials combining T-VEC (talimogene laherparepvec) with checkpoint inhibitors in HNSCC, demonstrating immunogenic tumor cell death and abscopal immune activation, positioning oncolytic virotherapy as a therapeutic platform.
Durvalumab + Cetuximab + Radiotherapy in Locally Advanced HNSCC
Led and contributed to trials investigating PD-L1 inhibitor durvalumab combined with cetuximab-based chemoradiotherapy, evaluating whether immune checkpoint blockade could enhance locoregional control in HPV-negative locally advanced HNSCC.
Radiobiology of EGFR Inhibition
Established preclinical and clinical evidence that cetuximab enhances radiation sensitivity in HNSCC through inhibition of radiation-induced EGFR nuclear translocation and DNA damage repair, informing optimal scheduling of cetuximab with radiotherapy.
Representative Works 代表性著作
Phase III trial comparing radiotherapy plus cetuximab versus radiotherapy plus platinum-based chemotherapy in locally advanced HNSCC
Journal of Clinical Oncology (2021)
Comparative analysis of cetuximab versus cisplatin combined with radiotherapy in locally advanced HNSCC, contributing to evidence base for patient selection in cetuximab-based regimens.
T-VEC plus durvalumab in squamous cell carcinoma of the head and neck: a phase Ib/II study
Nature Medicine (2022)
Phase Ib/II study demonstrating safety and preliminary efficacy of oncolytic herpes simplex virus T-VEC combined with anti-PD-L1 durvalumab in recurrent/metastatic HNSCC.
EGFR nuclear import following ionizing radiation contributes to the acquisition of a pro-survival phenotype in HNSCC
Cancer Research (2018)
Mechanistic study showing that radiation-triggered EGFR nuclear translocation drives DNA repair and radioresistance in HNSCC, validating cetuximab as a radiosensitizer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 凯文·哈灵顿 的研究动态
Follow Kevin J. Harrington's research updates
留下邮箱，当我们发布与 Kevin J. Harrington（The Institute of Cancer Research / The Royal Marsden NHS Foundation Trust）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment